CERO THERAPEUTICS HOLDINGS, INC. Net Income (Loss) Available to Common Stockholders, Basic
CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Net Income (Loss) Available to Common Stockholders, Basic of -$29.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-14
- CERO THERAPEUTICS HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$29.46M.
- CERO THERAPEUTICS HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$5.89M.
- CERO THERAPEUTICS HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$11.51M.
- CERO THERAPEUTICS HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$30.12M.
- CERO THERAPEUTICS HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$7.29M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 1 month | Net Income (Loss) Available to Common Stockholders, Basic 2 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 5 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 7 month | Net Income (Loss) Available to Common Stockholders, Basic 8 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 11 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$29.46M 10-Q · filed 2026-08-14 | -$35.34M 10-Q · filed 2026-08-14 | ||||||||
| 2026-03-31 | -$5.89M 10-Q · filed 2026-05-15 | |||||||||
| 2025-09-30 | -$11.51M 10-Q · filed 2025-11-19 | -$41.62M derived: sum of 2 quarters · filed 2026-08-14 | -$47.08M 10-Q · filed 2025-11-19 | |||||||
| 2025-06-30 | -$30.12M 10-Q · filed 2026-08-14 | -$35.57M 10-Q · filed 2026-08-14 | ||||||||
| 2025-03-31 | -$5.45M 10-Q · filed 2026-05-15 | |||||||||
| 2024-12-31 | -$10.52M 10-K · filed 2025-04-15 | |||||||||
| 2024-09-30 | -$4.23M 10-Q · filed 2025-11-19 | -$6.68M derived: sum of 2 quarters · filed 2025-11-19 | -$8.40M 10-Q · filed 2025-11-19 | |||||||
| 2024-06-30 | -$2.45M 10-Q · filed 2025-08-22 | -$4.18M 10-Q · filed 2025-08-22 | ||||||||
| 2024-03-31 | -$1.73M 10-Q · filed 2025-05-15 | |||||||||
| 2024-02-13 | -$572.21K 10-Q · filed 2025-11-19 | |||||||||
| 2023-12-31 | -$7.29M 10-K · filed 2025-04-15 | |||||||||
| 2021-12-31 | -$21.41M 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |